Michael Schmidt
Stock Analyst at Guggenheim
(4.96)
# 29
Out of 5,139 analysts
112
Total ratings
74.71%
Success rate
53.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics | Maintains: Buy | $16 → $34 | $23.71 | +43.40% | 2 | Jan 8, 2026 | |
| IMNM Immunome | Maintains: Buy | $25 → $35 | $22.41 | +56.18% | 4 | Dec 16, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $6.02 | +99.34% | 1 | Nov 7, 2025 | |
| INCY Incyte | Upgrades: Buy | $125 | $106.21 | +17.69% | 7 | Nov 3, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $32.25 | +33.33% | 3 | Sep 23, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Buy | $10 | $3.62 | +176.24% | 6 | Aug 13, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Buy | $18 | $12.12 | +48.51% | 6 | Aug 13, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $10 → $12 | $5.70 | +110.53% | 5 | Aug 12, 2025 | |
| ONC BeOne Medicines AG | Maintains: Buy | $350 → $365 | $338.19 | +7.93% | 4 | Aug 7, 2025 | |
| ARVN Arvinas | Maintains: Buy | $16 → $15 | $12.20 | +22.95% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $10 | $13.01 | -23.14% | 1 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $38.94 | -56.34% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $120.28 | -33.49% | 4 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $20.86 | +115.72% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $15 | $18.80 | -20.21% | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $69.54 | -25.22% | 1 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $7.35 | +36.05% | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $20.52 | +55.95% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $20.99 | -61.89% | 2 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $6.68 | +109.58% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $22.14 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $43.96 | -4.46% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.17 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.01 | +299.20% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $2.96 | +170.27% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.35 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $112 | $8.28 | +1,252.66% | 4 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.36 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.58 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.63 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $12.79 | +165.83% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $9.62 | +159.88% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $3.36 | +673.81% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.07 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $27.19 | +194.23% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.61 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $4.06 | +35.47% | 2 | Nov 7, 2017 |
Monte Rosa Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $16 → $34
Current: $23.71
Upside: +43.40%
Immunome
Dec 16, 2025
Maintains: Buy
Price Target: $25 → $35
Current: $22.41
Upside: +56.18%
Foghorn Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $12
Current: $6.02
Upside: +99.34%
Incyte
Nov 3, 2025
Upgrades: Buy
Price Target: $125
Current: $106.21
Upside: +17.69%
Genmab
Sep 23, 2025
Upgrades: Buy
Price Target: $43
Current: $32.25
Upside: +33.33%
ADC Therapeutics
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $3.62
Upside: +176.24%
ORIC Pharmaceuticals
Aug 13, 2025
Reiterates: Buy
Price Target: $18
Current: $12.12
Upside: +48.51%
Compass Therapeutics
Aug 12, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $5.70
Upside: +110.53%
BeOne Medicines AG
Aug 7, 2025
Maintains: Buy
Price Target: $350 → $365
Current: $338.19
Upside: +7.93%
Arvinas
Aug 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $12.20
Upside: +22.95%
Aug 6, 2025
Maintains: Buy
Price Target: $8 → $10
Current: $13.01
Upside: -23.14%
Jul 8, 2025
Reiterates: Buy
Price Target: $17
Current: $38.94
Upside: -56.34%
Jun 25, 2025
Reiterates: Buy
Price Target: $80
Current: $120.28
Upside: -33.49%
Jun 24, 2025
Reiterates: Buy
Price Target: $45
Current: $20.86
Upside: +115.72%
May 23, 2025
Maintains: Buy
Price Target: $40 → $15
Current: $18.80
Upside: -20.21%
May 12, 2025
Reiterates: Buy
Price Target: $52
Current: $69.54
Upside: -25.22%
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $7.35
Upside: +36.05%
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $20.52
Upside: +55.95%
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $20.99
Upside: -61.89%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $6.68
Upside: +109.58%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $22.14
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $43.96
Upside: -4.46%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.17
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $5.01
Upside: +299.20%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $2.96
Upside: +170.27%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $33.35
Upside: -
Sep 30, 2024
Upgrades: Buy
Price Target: $112
Current: $8.28
Upside: +1,252.66%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.36
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.58
Upside: -
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.63
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $12.79
Upside: +165.83%
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $9.62
Upside: +159.88%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $3.36
Upside: +673.81%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.07
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $27.19
Upside: +194.23%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $9.61
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $4.06
Upside: +35.47%